Back to Search
Start Over
Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium.
- Source :
-
Pediatric blood & cancer [Pediatr Blood Cancer] 2020 Jun; Vol. 67 (6), pp. e28222. Date of Electronic Publication: 2020 Mar 24. - Publication Year :
- 2020
-
Abstract
- Background: Regorafenib is a small molecule multikinase inhibitor that inhibits multiple kinases including BRAF, KIT, PDGFRB, RAF, RET, and VEGFR1-3.<br />Procedures: The in vivo anticancer effects of regorafenib were assessed in a panel of six osteosarcoma models, three rhabdomyosarcoma models, and one Ewing sarcoma model.<br />Results: Regorafenib induced modest inhibition of tumor growth in the models evaluated.<br />Conclusion: The overall pattern of response to regorafenib appears similar to that of the kinase inhibitor sorafenib, with pronounced slowing of tumor growth in some models, limited to the period of agent administration, being the primary treatment effect.<br /> (© 2020 Wiley Periodicals, Inc.)
- Subjects :
- Animals
Apoptosis
Bone Neoplasms enzymology
Bone Neoplasms pathology
Cell Proliferation
Child
Female
Humans
Mice
Mice, SCID
Osteosarcoma enzymology
Osteosarcoma pathology
Rhabdomyosarcoma enzymology
Rhabdomyosarcoma pathology
Sarcoma, Ewing enzymology
Sarcoma, Ewing pathology
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Bone Neoplasms drug therapy
Osteosarcoma drug therapy
Phenylurea Compounds pharmacology
Protein Kinase Inhibitors pharmacology
Pyridines pharmacology
Rhabdomyosarcoma drug therapy
Sarcoma, Ewing drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1545-5017
- Volume :
- 67
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Pediatric blood & cancer
- Publication Type :
- Academic Journal
- Accession number :
- 32207565
- Full Text :
- https://doi.org/10.1002/pbc.28222